Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of “Buy” by Analysts

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $48.20.

Several analysts have weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $50.00 price target on shares of Outlook Therapeutics in a research note on Friday, October 18th. Ascendiant Capital Markets lowered their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Chardan Capital restated a “buy” rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research report on Thursday, August 15th.

Insider Activity at Outlook Therapeutics

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was bought at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the acquisition, the chief financial officer now directly owns 5,946 shares in the company, valued at $33,832.74. The trade was a 528.54 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.40% of the stock is owned by company insiders.

Institutional Trading of Outlook Therapeutics

Several large investors have recently added to or reduced their stakes in OTLK. Great Point Partners LLC raised its holdings in Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Rosalind Advisors Inc. boosted its position in Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock valued at $3,321,000 after acquiring an additional 138,225 shares in the last quarter. Geode Capital Management LLC boosted its position in Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after acquiring an additional 112,812 shares in the last quarter. LVW Advisors LLC purchased a new position in shares of Outlook Therapeutics during the 2nd quarter worth approximately $352,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics in the 2nd quarter worth approximately $303,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Stock Performance

Shares of OTLK opened at $5.03 on Friday. Outlook Therapeutics has a fifty-two week low of $4.61 and a fifty-two week high of $12.85. The firm has a market cap of $119.01 million, a price-to-earnings ratio of -0.47 and a beta of 0.62. The firm has a 50 day moving average price of $5.58 and a 200-day moving average price of $6.88.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.